132 related articles for article (PubMed ID: 9576202)
1. Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma.
Bernell P; Ohm L
Br J Haematol; 1998 Apr; 101(1):203-4. PubMed ID: 9576202
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.
Dumontet C; Morschhauser F; Solal-Celigny P; Bouafia F; Bourgeois E; Thieblemont C; Leleu X; Hequet O; Salles G; Coiffier B
Br J Haematol; 2001 Jun; 113(3):772-8. PubMed ID: 11380469
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma.
Fosså A; Santoro A; Hiddemann W; Truemper L; Niederle N; Buksmaui S; Bonadonna G; Seeber S; Nowrousian MR
J Clin Oncol; 1999 Dec; 17(12):3786-92. PubMed ID: 10577850
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma.
Emmanouilides C; Colovos C; Pinter-Brown L; Hernandez L; Schiller G; Territo M; Rosen P
Clin Lymphoma; 2004 Jun; 5(1):45-9. PubMed ID: 15245607
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma.
Zlotnick M; Avigdor A; Ribakovsky E; Nagler A; Kedmi M
Acta Haematol; 2019; 141(2):84-90. PubMed ID: 30630175
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of gemcitabine in patients with relapsed or refractory low-grade non-Hodgkin lymphoma.
Larson BJ; Waples JM; Pusateri A; Mendenhall NP; Lynch JW
Am J Clin Oncol; 2005 Apr; 28(2):165-8. PubMed ID: 15803011
[TBL] [Abstract][Full Text] [Related]
7. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.
Bai B; Huang HQ; Cai QQ; Wang XX; Cai QC; Lin ZX; Gao Y; Xia Y; Bu Q; Guo Y
Med Oncol; 2013 Mar; 30(1):350. PubMed ID: 23329307
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine for relapsed or resistant lymphoma.
Savage DG; Rule SA; Tighe M; Garrett TJ; Oster MW; Lee RT; Ruiz J; Heitjan D; Keohan ML; Flamm M; Johnson SA
Ann Oncol; 2000 May; 11(5):595-7. PubMed ID: 10907954
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
10. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma.
Venkatesh H; Di Bella N; Flynn TP; Vellek MJ; Boehm KA; Asmar L
Clin Lymphoma; 2004 Sep; 5(2):110-5. PubMed ID: 15453926
[TBL] [Abstract][Full Text] [Related]
11. Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine.
Sezer O; Eucker J; Jakob C; Kaufmann O; Schmid P; Possinger K
Invest New Drugs; 2001; 19(1):101-4. PubMed ID: 11291828
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and its combinations in the treatment of malignant lymphoma.
Chau I; Watkins D; Cunningham D
Clin Lymphoma; 2002 Sep; 3(2):97-104. PubMed ID: 12435288
[TBL] [Abstract][Full Text] [Related]
13. [Gemcitabine in the treatment of relapsed or refractory non-Hodgkin's lymphoma].
Ma S; Sheng X; Luo R; Li A
Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):619-20. PubMed ID: 12667341
[TBL] [Abstract][Full Text] [Related]
14. Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Eom HS; Kim JS; Lee YY; Oh SJ; Lee DH; Suh C
Invest New Drugs; 2011 Feb; 29(1):154-60. PubMed ID: 19756371
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study.
Müller-Beissenhirtz H; Kasper C; Nückel H; Dührsen U
Ann Hematol; 2005 Nov; 84(12):796-801. PubMed ID: 16041531
[TBL] [Abstract][Full Text] [Related]
16. Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL.
el Aziz LM
Med Oncol; 2014 Nov; 31(11):244. PubMed ID: 25294423
[TBL] [Abstract][Full Text] [Related]
17. Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma?
Wenger C; Stern M; Herrmann R; Rochlitz Ch; Pless M
Leuk Lymphoma; 2005 Jan; 46(1):71-5. PubMed ID: 15621783
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.
Santoro A; Magagnoli M; Spina M; Pinotti G; Siracusano L; Michieli M; Nozza A; Sarina B; Morenghi E; Castagna L; Tirelli U; Balzarotti M
Haematologica; 2007 Jan; 92(1):35-41. PubMed ID: 17229633
[TBL] [Abstract][Full Text] [Related]
19. [The role of gemcitabine in hematology].
Dumontet C
Bull Cancer; 2002 Aug; 89 Spec No():S123-6. PubMed ID: 12449043
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients.
Lund B; Hansen OP; Neijt JP; Theilade K; Hansen M
Anticancer Drugs; 1995 Dec; 6 Suppl 6():61-2. PubMed ID: 8718427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]